IL2 and neoplasm: Although IL-2/JES6 has not been extensively tested in tumor models due to its biased expansion of Treg cells, we recently showed that IL-2/JES6 considerably improved doxorubicin-based chemotherapy in the mouse syngeneic B16F10 melanoma and BCL1 leukemia models.29